PROTAGONIST THERAPEUTICS INC |
End-of-day quote
Other stock markets
|
||
| - PTS | - |
|
Chart calendar Protagonist Therapeutics Inc
b143fd64fa1a6b4a3e.UUylXK6vO7EPThtDtRXMYKTR5unKi51egApN3X6d-q8.CRndGMycWoVZeGkm-E2qJ5Onua6f-9cuuFIO6gjzjfdgfOME4shN8n96dA~b2fe3d4039e0042ced9c0bdd4ca61c88
Upcoming events on Protagonist Therapeutics Inc
Past events on Protagonist Therapeutics Inc
| 2024-03-28 01:00 pm | H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference |
| 2024-03-26 01:30 pm | Napa Valley Biotech Forum |
| 2024-03-11 | Jefferies Biotech on the Bay Summit |
| 2024-03-10 | American Academy of Dermatology Meeting |
| 2024-02-27 04:05 pm | Q4 2023 Earnings Release |
| 2024-02-08 09:00 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-31 04:30 pm | Business Update Call |
| 2024-01-09 12:45 pm | JPMorgan Healthcare Conference |
| 2023-12-11 01:30 pm | American Society of Hematology Meeting - Session Name: 634 |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting - Session Name: 634 |
| 2023-12-09 08:30 pm | American Society of Hematology Meeting - Session Name: 113 |
| 2023-12-09 01:30 pm | American Society of Hematology Meeting - Session Name: 904 |
| 2023-11-14 04:00 am | Jefferies London Healthcare Conference - Fireside Chat |
| 2023-11-09 02:25 pm | Truist Securities Healthcare Conference - Panel |
| 2023-11-06 | J.P. Morgan Equity Opportunities Forum |
| 2023-11-06 11:10 am | Guggenheim Securities Inflammation & Immunology Conference - Fireside Chat |
| 2023-11-02 12:00 am | Q3 2023 Earnings Release |
| 2023-11-01 | Myeloproliferative Neoplasms International Congress |
| 2023-09-12 12:00 am | H.C. Wainwright Global Investment Conference |
| 2023-08-03 04:05 pm | Q2 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,23 1,74 -86.69% | 28,6 25,7 11.45% | 27,4 23,2 17.93% | 26,6 31,4 -15.46% | 60,0 30,0 100% | 208 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -63,7 -68,7 7.22% | -125 -135 7.38% | 0,00 0,00 - | -92,7 -96,0 3.46% | -144 |
|
EBIT Million USD | Released Forecast Spread | -80,5 -81,8 1.55% | -64,5 -65,4 1.29% | -126 -128 1.54% | -131 -125 -5.35% | -93,7 -127 26.5% | 40,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -77,9 -79,3 1.83% | -64,8 -64,1 -1.11% | -126 -128 2.06% | -127 -127 -0.41% | -79,0 -116 31.76% | 83,4 |
|
Net income Million USD | Released Forecast Spread | -77,2 -77,9 0.89% | -66,2 -66,2 0.04% | -126 -128 1.93% | -127 -123 -3.53% | -79,0 -115 31.24% | 44,9 |
|
EPS USD | Released Forecast Spread | -2,98 -3,00 0.6% | -1,92 -1,94 0.84% | -2,71 -2,73 0.78% | -2,60 -2,49 -4.44% | -1,39 -2,02 31.28% | 0,72 |
| Announcement Date | 10/03/20 | 10/03/21 | 28/02/22 | 15/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 8,62 4,44 94.19% | 25,7 17,1 50.86% | 0,86 0,38 124.09% | 0,00 0,00 - | 0,00 5,00 - | 0,00 1,67 - | 0,00 0,00 - | 0,00 0,00 - | 60,0 30,0 100% | 120 | 60,0 | 0,00 | 9,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -36,8 -46,0 20.04% | -20,9 -50,0 58.28% | -41,2 -52,0 20.8% | -32,0 -43,0 25.5% | -36,3 -33,0 -9.88% | -35,8 -37,0 3.32% | -42,1 -37,0 -13.83% | -38,1 -43,0 11.44% | 23,3 21,0 10.94% | -38,0 | -38,0 | -39,0 | -30,0 | |
|
EBIT Million USD | Released Forecast Spread | -37,0 -39,0 5.05% | -21,1 -27,8 24.07% | -41,4 -46,3 10.55% | -32,3 -43,3 25.35% | -36,5 -29,0 -25.97% | -36,0 -36,3 0.65% | -42,4 -36,5 -15.94% | -38,3 -42,6 9.96% | 23,0 -10,1 328.49% | 36,9 | 30,6 | -40,6 | -30,8 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -36,9 -39,4 6.41% | -20,9 -31,6 33.77% | -41,0 -48,9 16.01% | -31,2 -41,7 25.09% | -34,2 -33,6 -1.71% | -33,7 -33,5 -0.69% | -38,5 -35,0 -9.97% | -34,1 -39,7 14.11% | 27,3 -8,04 440.04% | 114 | -37,1 | -38,4 | -16,8 | |
|
Net income Million USD | Released Forecast Spread | -36,9 -39,3 6.09% | -20,9 -30,4 31.15% | -41,0 -45,9 10.65% | -31,2 -43,0 27.39% | -34,2 -29,4 -16.27% | -33,7 -35,9 6.05% | -38,5 -35,5 -8.2% | -34,1 -40,2 15.17% | 27,3 -7,61 459.24% | 39,3 | 32,3 | -38,4 | -28,1 | |
|
EPS USD | Released Forecast Spread | -0,77 -0,79 2.35% | -0,43 -0,63 31.57% | -0,84 -0,94 10.17% | -0,64 -0,87 26.31% | -0,69 -0,59 -16.49% | -0,67 -0,73 7.78% | -0,68 -0,65 -5.22% | -0,58 -0,69 16.27% | 0,44 -0,14 406.9% | 1,19 | 0,34 | -0,63 | -0,51 | -0,77 |
| Announcement Date | 28/02/22 | 04/05/22 | 04/08/22 | 08/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 27/02/24 | - | - | - | - | - |
| Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
| 2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
| 2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Protagonist Therapeutics Inc
- Stock Market
- Equities
- PTGX Stock
- Stock
- Calendar Protagonist Therapeutics Inc
